The University of Leicester’s Diabetes Centre are working with a medical device company who have provided funding for an investigator initiated study using a CE marked device in a new patient population.

Hybrid systems have been CE marked for use in type one diabetes, but we now want to test the efficacy and safety in type two diabetes. As this may open up a new indication, we suspect this study will require MHRA approval and an MHRA compatible database to store the study data.

We would love to hear from any companies who may be able to provide a suitable database for the study. In the first instance, please email iph@le.ac.uk so that we can arrange further conversations with the study team.

Opportunity provided by the University of Leicester

 

Latest Opportunities

Funding opportunity: Biomedical Catalyst 2024 Round 1

Innovate UK, part of UK Research and Innovation, will invest up to £15m in innovation…

Blue Zone Consortium offers new funding opportunities for its members

The 2024 Blue Zone Consortium Flexible Talent Mobility Award (FTMA) funding call is now open. …

Opportunity for companies to provide database study for University of Leicester’s Diabetes Centre

The University of Leicester’s Diabetes Centre are working with a medical device company who have…

Latest News

Cellular Origins and 3P innovation collaborate to accelerate industrialisation of CGT manufacturing

Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell…

Shakespeare Martineau expands healthcare expertise with six-member team

As part of its growth strategy, full-service law firm Shakespeare Martineau has significantly bolstered its…

Gallagher releases new guide for leadership teams in the life sciences sector

Gallagher’s Directors & Officers’ (D&O) Insurance Guide provides crucial insights to help safeguard leadership teams…